ArticleCommunications biology2026
RFX5 as a regulator of spatial chromatin contacts and gene expression.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RFX5 in cancer: context-dependent molecular functions and emerging translational relevance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The three-dimensional chromatin architecture is critical for gene regulation, yet factors beyond CCCTC-binding factor (CTCF) and cohesin remain poorly characterized. Here, we identify RFX5 as a novel regulator of chromatin organization. Using CRISPR-mediated RFX5 knockout A375 cells, together with RNA-seq, ChIP-seq, ATAC-seq, QHR-4C, and Hi-C, we demonstrate that RFX5 binds to promoters and enhancers, co-localizes with CTCF, RAD21, and H3K27ac, maintains chromatin accessibility, and preserves chromatin loop strength. RFX5 deletion alters the expression of ~2,000 genes, with strong suppression of cancer-associated genes and oncogenic pathways. Loss of RFX5 reduces CTCF/RAD21 occupancy and promoter accessibility at downregulated genes. Notably, RFX5 acts as an insulator to balance chromatin looping: its absence weakens enhancer-promoter contacts at oncogenic loci while enabling inappropriate long-range enhancer interactions at upregulated genes. Hi-C analysis reveals globally diminished loop strength, with only mild effects on TAD insulation and compartmentalization. These findings establish RFX5 as a key architectural factor that links 3D genome structure to transcriptional programs in cancer and immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.